Keros Therapeutics, Inc. (KROS) Tops Q3 EPS by 2c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q3 EPS of ($1.33), $0.02 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $8 thousand.

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Truist Securities Starts Matthews International (MATW) at Hold, 'We see risk/reward as more balanced'
• Dollar stores see mixed outlook ahead of earnings next week, Gordon Haskett comments